company background image
A

Agilent Technologies NYSE:A Stock Report

Last Price

US$121.61

Market Cap

US$36.0b

7D

-5.1%

1Y

-23.9%

Updated

27 Sep, 2022

Data

Company Financials +
A fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance6/6
Financial Health5/6
Dividends0/6

A Stock Overview

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.

Agilent Technologies Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Agilent Technologies
Historical stock prices
Current Share PriceUS$121.61
52 Week HighUS$165.68
52 Week LowUS$112.52
Beta1.07
1 Month Change-6.36%
3 Month Change3.15%
1 Year Change-23.95%
3 Year Change62.49%
5 Year Change86.66%
Change since IPO184.47%

Recent News & Updates

Sep 19
Does Agilent Technologies (NYSE:A) Have A Healthy Balance Sheet?

Does Agilent Technologies (NYSE:A) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Sep 14

Agilent Confirmed Its Leadership And Is Set For Further Gains (Technical Analysis)

Summary Agilent reached the price target I suggested in April and is now showing even more strength. The stock is a leader in its industry and the healthcare sector is among the strongest in 3 months. With 113% performance over the past 5 years, Agilent outperformed its reference index by almost seven times. The stock has most likely a 14% upside potential, with a price target seen at $160. Investment thesis Agilent Technologies (NYSE:A) lost about 37% of its value since its stock all-time high (ATH) at $179.57 on September 3, 2021, bottoming at $112.52 on June 22, 2022, showing significant relative strength since the beginning of May and increasing strong buy-side volume during the bottoming phase. The stock reached the price target I suggested in my first analysis and is now showing significant strength after a retracement to its most strong support levels. My most likely price target is set at $160, with 14% upside potential from its latest closing price. A quick look at the big picture The healthcare sector in the US is among the winners in the last 3 months, led by a rebound in biotechnology stocks, followed by companies in the diagnostics and research industry. finviz The NASDAQ Health Care Index (IXHC) bottomed on June 16 and mostly showed relative strength since, when compared to the main index, while recently consolidating after reaching its EMA200. Author, using TradingView Looking back even further, Agilent significantly outperformed its main reference indexes and funds, reporting 113.74% performance over the past 5 years, almost seven times the performance of the IXHC and more than double of the Health Care Select Sector SPDR (NYSEARCA:XLV). Author, using SeekingAlpha.com Where are we now? Since my last article 'Agilent: A Strong Leader With Great Opportunities', the stock broke the mentioned supports at $123 and further at $120, with a significant gap down on June 13, just before confirming its bottom on June 15. The stock has since formed a short-term reversal, confirming its price level over the EMA50, reaching the price target I set on April 15, and recently even confirming its level over the EMA200, while the latter is giving signs of flattening, which could confirm that the stock has formed a sound base from which continuing in its medium-term uptrend. Author, using TradingView Each important resistance has been overcome with conviction on higher volume, confirming the stock's relative strength, which seems now set for further strength, and may be confirmed by the MACD, which just crossed its signal line, pointing to positive momentum in the stock price action. The actual most important support level is set by the EMA200, while minor support can also be found at the recent overcome retracement level at $138.13 and $134.33. Further resistances are now located at $146.04 and the recent peak at $149. What is coming next I expect the stock to continue in its recent run, as the favorable momentum in its industry seems to be confirmed and the stock could attempt to overcome its recent highs. Source: Author, using TradingView The stock just completed its corrective phase, a new uptrend based on an Elliott motive phase has likely begun and is supported by the strong trend, set since the end of June. My calculations based on Fibonacci's theory, suggest the most likely price target at $160, as the first target at $139 has already been reached.

Sep 01

Agilent, Mettler-Toledo team up for solution to reduce errors in sample preparation

Agilent Technologies (NYSE:A) and Mettler-Toledo International (NYSE:MTD) are collaborating to reduce errors in sample preparation workflows for better chromatographic results. The integrated solution allows automatic and seamless transfer of weighing results and associated metadata from Mettler-Toledo LabX Balance software to Agilent's OpenLab software. The solution, which was launched in Munich in June, offers an LC or GC workflow aimed at eliminating common errors in the weighing process. "The seamless integration of balances and chromatography instruments in a digital and automated sample preparation and analysis process allows a drastic reduction or even elimination of transcription and calculation errors, significantly increasing lab productivity," said Mettler-Toledo CEO Patrick Kaltenbach.

Shareholder Returns

AUS Life SciencesUS Market
7D-5.1%-5.3%-5.8%
1Y-23.9%-32.7%-22.1%

Return vs Industry: A exceeded the US Life Sciences industry which returned -34.2% over the past year.

Return vs Market: A matched the US Market which returned -23.7% over the past year.

Price Volatility

Is A's price volatile compared to industry and market?
A volatility
A Average Weekly Movement4.8%
Life Sciences Industry Average Movement9.7%
Market Average Movement6.9%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: A is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: A's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199917,700Mike McMullenhttps://www.agilent.com

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide.

Agilent Technologies Fundamentals Summary

How do Agilent Technologies's earnings and revenue compare to its market cap?
A fundamental statistics
Market CapUS$36.00b
Earnings (TTM)US$1.33b
Revenue (TTM)US$6.66b

27.1x

P/E Ratio

5.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A income statement (TTM)
RevenueUS$6.66b
Cost of RevenueUS$3.05b
Gross ProfitUS$3.61b
Other ExpensesUS$2.28b
EarningsUS$1.33b

Last Reported Earnings

Jul 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)4.49
Gross Margin54.21%
Net Profit Margin19.94%
Debt/Equity Ratio57.2%

How did A perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

19%

Payout Ratio

Does A pay a reliable dividends?

See A dividend history and benchmarks
When do you need to buy A by to receive an upcoming dividend?
Agilent Technologies dividend dates
Ex Dividend DateOct 03 2022
Dividend Pay DateOct 26 2022
Days until Ex dividend4 days
Days until Dividend pay date27 days

Does A pay a reliable dividends?

See A dividend history and benchmarks
We’ve recently updated our valuation analysis.

Valuation

Is A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A?

Other financial metrics that can be useful for relative valuation.

A key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.7x
Enterprise Value/EBITDA19.8x
PEG Ratio2.6x

Price to Earnings Ratio vs Peers

How does A's PE Ratio compare to its peers?

A PE Ratio vs Peers
The above table shows the PE ratio for A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average27.3x
IQV IQVIA Holdings
29.4x18.4%US$34.1b
MTD Mettler-Toledo International
30.3x7.4%US$24.9b
WAT Waters
23.1x6.4%US$16.2b
WST West Pharmaceutical Services
26.6x9.0%US$18.2b
A Agilent Technologies
27.1x10.4%US$36.0b

Price-To-Earnings vs Peers: A is good value based on its Price-To-Earnings Ratio (27.1x) compared to the peer average (27.3x).


Price to Earnings Ratio vs Industry

How does A's PE Ratio compare vs other companies in the US Life Sciences Industry?

Price-To-Earnings vs Industry: A is expensive based on its Price-To-Earnings Ratio (27.1x) compared to the US Life Sciences industry average (25.3x)


Price to Earnings Ratio vs Fair Ratio

What is A's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.1x
Fair PE Ratio26x

Price-To-Earnings vs Fair Ratio: A is expensive based on its Price-To-Earnings Ratio (27.1x) compared to the estimated Fair Price-To-Earnings Ratio (26x).


Share Price vs Fair Value

What is the Fair Price of A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A ($121.61) is trading below our estimate of fair value ($133.33)

Significantly Below Fair Value: A is trading below fair value, but not by a significant amount.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Agilent Technologies forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


10.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: A's forecast earnings growth (10.4% per year) is above the savings rate (1.9%).

Earnings vs Market: A's earnings (10.4% per year) are forecast to grow slower than the US market (14.7% per year).

High Growth Earnings: A's earnings are forecast to grow, but not significantly.

Revenue vs Market: A's revenue (6% per year) is forecast to grow slower than the US market (7.6% per year).

High Growth Revenue: A's revenue (6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: A's Return on Equity is forecast to be high in 3 years time (28.2%)


Discover growth companies

Past Performance

How has Agilent Technologies performed over the past 5 years?

Past Performance Score

6/6

Past Performance Score 6/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


19.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A has high quality earnings.

Growing Profit Margin: A's current net profit margins (19.9%) are higher than last year (16.1%).


Past Earnings Growth Analysis

Earnings Trend: A's earnings have grown by 19.2% per year over the past 5 years.

Accelerating Growth: A's earnings growth over the past year (34.1%) exceeds its 5-year average (19.2% per year).

Earnings vs Industry: A earnings growth over the past year (34.1%) exceeded the Life Sciences industry 15.6%.


Return on Equity

High ROE: A's Return on Equity (26.1%) is considered high.


Discover strong past performing companies

Financial Health

How is Agilent Technologies's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: A's short term assets ($3.7B) exceed its short term liabilities ($1.9B).

Long Term Liabilities: A's short term assets ($3.7B) exceed its long term liabilities ($3.5B).


Debt to Equity History and Analysis

Debt Level: A's net debt to equity ratio (36%) is considered satisfactory.

Reducing Debt: A's debt to equity ratio has increased from 45.1% to 57.2% over the past 5 years.

Debt Coverage: A's debt is well covered by operating cash flow (44.8%).

Interest Coverage: A's interest payments on its debt are well covered by EBIT (20.7x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Agilent Technologies's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


0.69%

Current Dividend Yield

Upcoming Dividend Payment

TodaySep 28 2022Ex Dividend DateOct 03 2022Dividend Pay DateOct 26 202223 days from Ex DividendBuy in the next 4 days to receive the upcoming dividend

Dividend Yield vs Market

Agilent Technologies Dividend Yield vs Market
How does Agilent Technologies dividend yield compare to the market?
SegmentDividend Yield
Company (Agilent Technologies)0.7%
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Life Sciences)0.3%
Analyst forecast in 3 Years (Agilent Technologies)0.8%

Notable Dividend: A's dividend (0.69%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.67%).

High Dividend: A's dividend (0.69%) is low compared to the top 25% of dividend payers in the US market (4.68%).


Stability and Growth of Payments

Stable Dividend: A is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: A is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Earnings Payout to Shareholders

Earnings Coverage: A is not paying a notable dividend for the US market.


Cash Payout to Shareholders

Cash Flow Coverage: A is not paying a notable dividend for the US market.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.3yrs

Average management tenure


CEO

Mike McMullen (61 yo)

7.5yrs

Tenure

US$15,967,631

Compensation

Mr. Michael R. McMullen, also known as Mike, has been the President of Agilent Technologies, Inc., since September 17, 2014 and Chief Executive Officer since March 18, 2015. Mr. McMullen has been a Directo...


CEO Compensation Analysis

Mike McMullen's Compensation vs Agilent Technologies Earnings
How has Mike McMullen's remuneration changed compared to Agilent Technologies's earnings?
DateTotal Comp.SalaryCompany Earnings
Jul 31 2022n/an/a

US$1b

Apr 30 2022n/an/a

US$1b

Jan 31 2022n/an/a

US$1b

Oct 31 2021US$16mUS$1m

US$1b

Jul 31 2021n/an/a

US$990m

Apr 30 2021n/an/a

US$925m

Jan 31 2021n/an/a

US$810m

Oct 31 2020US$14mUS$1m

US$719m

Jul 31 2020n/an/a

US$691m

Apr 30 2020n/an/a

US$683m

Jan 31 2020n/an/a

US$764m

Oct 31 2019US$13mUS$1m

US$1b

Jul 31 2019n/an/a

US$1b

Apr 30 2019n/an/a

US$1b

Jan 31 2019n/an/a

US$1b

Oct 31 2018US$12mUS$1m

US$316m

Jul 31 2018n/an/a

US$298m

Apr 30 2018n/an/a

US$237m

Jan 31 2018n/an/a

US$196m

Oct 31 2017US$10mUS$1m

US$684m

Jul 31 2017n/an/a

US$633m

Apr 30 2017n/an/a

US$582m

Jan 31 2017n/an/a

US$509m

Oct 31 2016US$9mUS$1m

US$462m

Jul 31 2016n/an/a

US$476m

Apr 30 2016n/an/a

US$465m

Jan 31 2016n/an/a

US$466m

Oct 31 2015US$7mUS$846k

US$438m

Compensation vs Market: Mike's total compensation ($USD15.97M) is about average for companies of similar size in the US market ($USD13.05M).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: A's management team is seasoned and experienced (7.3 years average tenure).


Board Members

Experienced Board: A's board of directors are considered experienced (7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: A insiders have only sold shares in the past 3 months.


Recent Insider Transactions

NYSE:A Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
09 Sep 22SellUS$802,571Jacob ThaysenIndividual5,839US$137.45
08 Sep 22SellUS$336,641Padraig McDonnellIndividual2,506US$134.33
30 Jun 22SellUS$118,625Padraig McDonnellIndividual1,000US$118.63
02 Jun 22SellUS$749,179Jacob ThaysenIndividual5,879US$127.43
18 Mar 22SellUS$164,814Michael TangIndividual1,210US$136.21
29 Dec 21SellUS$590,709Dominique GrauIndividual3,669US$161.00
20 Dec 21SellUS$18,373,168Michael McMullenIndividual123,459US$148.82
02 Dec 21SellUS$121,512Rodney GonsalvesIndividual800US$151.89
30 Nov 21SellUS$106,274Rodney GonsalvesIndividual699US$152.04

Ownership Breakdown

What is the ownership structure of A?
Owner TypeNumber of SharesOwnership Percentage
State or Government134,9010.05%
Individual Insiders816,6370.3%
General Public30,496,86410.3%
Institutions264,592,16889.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 56.29% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.92%
BlackRock, Inc.
32,314,037$3.9b7.42%0.1%
8.34%
The Vanguard Group, Inc.
24,698,265$3.0b0.68%0.07%
5.63%
T. Rowe Price Group, Inc.
16,652,764$2.0b1.36%0.24%
4.42%
State Street Global Advisors, Inc.
13,078,800$1.6b-0.84%0.09%
4.23%
Wellington Management Group LLP
12,534,755$1.5b15.78%0.28%
1.98%
Massachusetts Financial Services Company
5,851,153$711.6m42.19%0.19%
1.97%
Geode Capital Management, LLC
5,837,281$709.9m0.8%0.09%
1.85%
Pictet Asset Management Limited
5,476,317$666.0m4.08%0.61%
1.42%
Northern Trust Global Investments
4,214,994$512.6m-2.83%0.11%
1.41%
Impax Asset Management Group plc
4,168,528$506.9m-3.17%1.7%
1.33%
State Farm Insurance Companies, Asset Management Arm
3,950,809$480.5m0%0.56%
1.17%
Cantillon Capital Management LLC
3,458,756$420.6m-0.32%3.51%
1.05%
Principal Global Investors, LLC
3,115,931$378.9m62.45%0.27%
1.03%
FMR LLC
3,054,250$371.4m14.43%0.04%
1.02%
Eaton Vance Management
3,027,768$368.2m6.04%0.14%
1%
Legal & General Investment Management Limited
2,957,465$359.7m-1.53%0.11%
0.96%
Norges Bank Investment Management
2,854,695$347.2m0%0.05%
0.89%
BNY Mellon Asset Management
2,631,921$320.1m2.77%0.07%
0.86%
PRIMECAP Management Company
2,553,961$310.6m-1.86%0.29%
0.84%
Parnassus Investments, LLC
2,482,976$302.0m-7.19%0.76%
0.83%
Deutsche Asset & Wealth Management
2,468,545$300.2m4.06%0.13%
0.81%
Winslow Capital Management, LLC
2,411,679$293.3m403.54%1.91%
0.8%
Invesco Ltd.
2,372,095$288.5m-15.33%0.1%
0.78%
Goldman Sachs Asset Management, L.P.
2,299,939$279.7m25.94%0.12%
0.74%
UBS Asset Management
2,179,008$265.0m-9.9%0.05%

Company Information

Agilent Technologies, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Agilent Technologies, Inc.
  • Ticker: A
  • Exchange: NYSE
  • Founded: 1999
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$36.001b
  • Shares outstanding: 296.04m
  • Website: https://www.agilent.com

Number of Employees


Location

  • Agilent Technologies, Inc.
  • 5301 Stevens Creek Boulevard
  • Santa Clara
  • California
  • 95051
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ANYSE (New York Stock Exchange)YesCommon StockUSUSDNov 1999
AG8DB (Deutsche Boerse AG)YesCommon StockDEEURNov 1999
A *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNNov 1999
0HAVLSE (London Stock Exchange)YesCommon StockGBUSDNov 1999
AG8ETLX (Eurotlx)YesCommon StockITEURNov 1999
ABVL (Bolsa de Valores de Lima)YesCommon StockPEUSDNov 1999
A1GI34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 2 REPR 1 SHS UNSPONBRBRLJan 2020

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/27 00:00
End of Day Share Price2022/09/27 00:00
Earnings2022/07/31
Annual Earnings2021/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.